Scholarlink

<p>Vorasidenib offers a&#xa0;novel treatment option for patients who wish to delay radiotherapy and chemotherapy after surgery for various reasons. Vorasidenib demonstrated significantly improved progression-free survival and time to next intervention, reduced tumor volume, maintenance of patient-reported health-related quality of life, and improved seizure control, as well as a&#xa0;manageable safety profile. The INDIGO trial as a&#xa0;landmark study is presented in the current review article. Isocitrate dehydrogenase (IDH) inhibitor-based therapy is an additional new therapeutic option for IDH-mutated diffuse glioma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Isocitrate dehydrogenase inhibition in glioma

  • 期刊论文

  • 发表日期：

    2025年9月4日

查看全文
  • Josef Pichler

摘要

Vorasidenib offers a novel treatment option for patients who wish to delay radiotherapy and chemotherapy after surgery for various reasons. Vorasidenib demonstrated significantly improved progression-free survival and time to next intervention, reduced tumor volume, maintenance of patient-reported health-related quality of life, and improved seizure control, as well as a manageable safety profile. The INDIGO trial as a landmark study is presented in the current review article. Isocitrate dehydrogenase (IDH) inhibitor-based therapy is an additional new therapeutic option for IDH-mutated diffuse glioma.